Naoko Tanaka
Bcma soluble levels predicts outcome in triple-class exposed myeloma
Gabriela Moreira
Multi-omic characterization of lineage priming in early progenitors in human cord blood
Irene Rubio
Real-world effectiveness of cold-stored platelets in preterm neonates: a multicenter multinational cohort
Scott Thomas
Long-term outcomes of relapsed CLL after covalent BTK inhibitors treated with fixed-duration venetoclax: a Dutch registry study of 412 patients
Julie Guerin
Mezoridomide plus daratumumab, bortezomib, lenalidomide and dexamethasone in relapsed/refractory multiple myeloma after three prior lines: phase 1 results of the PRISM-5 trial
Christos Angelopoulos
Multi-omic characterization of BCR signalling rewiring in relapsed CLL after covalent BTK inhibitors
Pablo Gil
Long-term outcomes of pyruvate kinase deficiency treated with iron chelation: a international registry study of 2105 patients
Sophie Edwards
Glovutamab plus R-CHOP in previously untreated follicular lymphoma: phase 2 results of the PRISM-2 trial
Pilar Alonso
Real-world effectiveness of efactocog beta in patients with antiphospholipid syndrome: a multicenter dutch cohort
Johanna Krüger
Health-related quality of life in adults with newly diagnosed AML receiving intensive induction: a prospective french study
Benjamin Wright
Efficacy and safety of quelcitamab in older adults with secondary AML: primary analysis of the phase 3 NORDLYS-2 study
Antonio Villa
Treatment patterns and survival in haploidentical transplant recipients: real-world data from the Italian allo-HSCT registry
Mirza Popović
Efficacy and safety of ravotuzumab vedotin in adults with newly diagnosed AML receiving intensive induction: primary analysis of the randomized phase 3 ALTITUDE-1 study
Romain Henry
Targeting lineage priming in early progenitors in normal and malignant hematopoiesis: preclinical evidence
Anja Peters
Ravelinib plus imatinib in chronic-phase CML in deep molecular response: phase 3 results of the VALOR-8 trial
Sebastian Meier
Olorofim plus standard supportive care in patients receiving CAR T-cell therapy: phase 2 results of the BEACON-5 trial
Joost Janssen
Single-cell profiling reveals inflammasome activation in myelodysplastic syndromes (MDS)
Stefan Marić
A federated learning platform compared with expert morphological review on patients with suspected myeloid neoplasms: a prospective multicenter evaluation
Martin Novák
Prognostic value of circulating tumor DNA in classic Hodgkin lymphoma: results from ECLIPSE-7
Felix Roth
Real-world effectiveness of NK-501 in patients receiving CD19-directed CAR T-cell therapy: a multicenter french cohort
Christina Braun
Single-cell profiling reveals leukemia-niche interactions in acute lymphoblastic leukemia (ALL)
Émilie Lambert
Itovazumab plus anti-thymocyte globulin in older recipients of reduced-intensity conditioning: phase 1b/2 results of the MERIDIAN-8 trial
Thomas Murray
Efficacy and safety of glovutamab in mantle cell lymphoma after BTK inhibitor failure: primary analysis of the phase 1b/2 HORIZON-6 study
Claudia Wolf
Telvostat versus erythropoiesis-stimulating agents in MDS with SF3B1 mutation (TRIDENT-8): a phase 2 trial
Pietro Vitale
Prognostic value of ferritin in donors in patients with massive hemorrhage: results from BEACON-6
Stefanie Schröder
Rusperatide plus hydroxyurea in myelofibrosis after ruxolitinib failure: phase 1b/2 results of the ATLAS-6 trial
Michael Meyer
Long-term outcomes of lower-risk MDS with transfusion-dependent anemia treated with luspatercept: a Dutch registry study of 188 patients
Sophie Koch
Treatment patterns and survival in adults with Philadelphia chromosome-positive ALL: real-world data from the French ALL registry
Emre Kaya
Real-world effectiveness of ravelinib in newly diagnosed chronic-phase CML: a multicenter dutch cohort
Giuseppe Serra
Vaso-occlusive crisis rate predicts outcome in adults with sickle cell disease
Arnaud Bernard
Targeting treatment-free remission biology in chronic myeloid leukemia (CML): preclinical evidence
Alexander Neumann
Real-world effectiveness of lovotigene autotemcel in patients with sickle cell disease treated with gene editing: a multicenter french cohort
Joon-young Kwon
Health-related quality of life in patients receiving CAR T-cell therapy: a prospective british study
Thomas Huber
Multi-omic characterization of tissue factor pathway regulation in hemophilia B
Nathalie Lambert
Efficacy and safety of glovutamab in previously untreated follicular lymphoma: primary analysis of the randomized phase 3 TRIDENT-9 study
Marta Pereira
Ponavatinib plus blinatumomab in adults with Philadelphia chromosome-positive ALL: phase 2 results of the ECLIPSE-9 trial
Daniel Richter
Hepcidin levels predicts outcome in pyruvate kinase deficiency
Christian Schulz
Ighv mutational status predicts outcome in CLL with del(17p) or TP53 mutation
Claudia Hofmann
Luspaterpin versus azacitidine in MDS with SF3B1 mutation (ALTITUDE-6): a randomized phase 3 trial
Adam Mazur
Nk-501 plus busulfan myeloablation in patients receiving CD19-directed CAR T-cell therapy: randomized phase 3 results of the TRIDENT-5 trial
Gabriela Pereira
Health-related quality of life in patients undergoing cardiac surgery: a prospective german study
Lena Roth
Long-term outcomes of MDS with SF3B1 mutation treated with azacitidine: a French registry study of 812 patients
Hannah Shaw
Single-cell profiling reveals epigenetic memory after infection in normal and malignant hematopoiesis
Anja Scholz
A large language model assistant compared with standard diagnostic workup on multicenter flow cytometry datasets: a prospective multicenter evaluation
Sophie Möller
Health-related quality of life in patients receiving CD19-directed CAR T-cell therapy: a prospective nordic study
Amit Katz
Prognostic value of Ph-like signatures in T-cell ALL: results from NORDLYS-8
Michael Baker
Long-term outcomes of adults with immune thrombocytopenia treated with emicizumab prophylaxis: a Italian registry study of 188 patients
Alexander Schneider
Long-term outcomes of people with severe hemophilia A treated with low-molecular-weight heparin: a Dutch registry study of 1240 patients
Zahra Ahmadi
Real-world effectiveness of cold-stored platelets in preterm neonates: a multicenter multinational cohort
Emma Robinson
Single-cell profiling reveals red cell storage lesion in transfusion practice
Joshua Allen
Validation of a large language model assistant for the diagnosis of myeloid neoplasms across 47 centers
Thomas Fischer
Hsc quiescence markers predicts outcome in patients with clonal hematopoiesis of indeterminate potential
Álvaro Marín
Prognostic value of platelet count increment in patients undergoing cardiac surgery: results from SAGA-4
Rasmus Jørgensen
Efficacy and safety of momavotinib in myelofibrosis after ruxolitinib failure: primary analysis of the randomized phase 3 NORDLYS-2 study
Daniel Brown
A deep-learning cytomorphology model compared with standard diagnostic workup on multicenter flow cytometry datasets: a prospective multicenter evaluation
Stefan Hahn
Validation of a deep-learning cytomorphology model for automated classification of bone marrow cells across 19 centers
Laura Conte
Efficacy and safety of ibrexitamab in T-cell ALL: primary analysis of the randomized phase 2 CORONA-4 study
Bruno Costa
Rilvabrutinib versus direct oral anticoagulants in patients with antiphospholipid syndrome (ALTITUDE-5): a phase 2 trial
Nikhil Menon
Odrolimab versus R-CHOP in mantle cell lymphoma after BTK inhibitor failure (AURORA-7): a phase 1 trial
Jessica Harris
Multi-omic characterization of BCR signalling rewiring in treatment-naive CLL
Karl Eriksson
Targeting financial toxicity in hematologic malignancies: preclinical evidence
Michael Bauer
Real-world effectiveness of glovutamab in primary CNS lymphoma: a multicenter german cohort
Rania Farouk
Multi-omic characterization of inflammatory aging of the stem cell niche in human cord blood
Antoine David
Validation of a large language model assistant for early detection of acute leukemia across 28 centers
Pietro Romano
Multi-omic characterization of lineage priming in early progenitors in healthy donors
Alejandro Blanco
Prognostic value of inflammatory memory in human cord blood: results from HELIOS-3
Daniel Lehmann
Single-cell profiling reveals inflammatory aging of the stem cell niche in normal and malignant hematopoiesis
Sophie de Vries
Nelbrutinib plus fixed-duration venetoclax in relapsed CLL after covalent BTK inhibitors: randomized phase 3 results of the MERIDIAN-6 trial
Marie Friedrich
Targeting bone marrow stromal support in multiple myeloma: preclinical evidence
Mihai Popa
Health-related quality of life in adults with Philadelphia chromosome-positive ALL: a prospective british study
Anna Beck
Prognostic value of infection-related mortality in older patients with hematologic cancers: results from VALOR-6
Akiko Yamamoto
Itovazumab plus post-transplant cyclophosphamide in patients with steroid-refractory acute graft-versus-host disease: randomized phase 3 results of the VIKING-4 trial
Robert Green
Vaso-occlusive crisis rate predicts outcome in non-transfusion-dependent beta-thalassemia
Oliver Cooper
Circulating tumor dna predicts outcome in mantle cell lymphoma after BTK inhibitor failure
Roberta Santoro
Treatment patterns and survival in treatment-naive CLL: real-world data from the multinational CLL registry
Christian Schneider
Treatment patterns and survival in patients with steroid-refractory acute graft-versus-host disease: real-world data from the Nordic allo-HSCT registry
Mikko Heinonen
Treatment patterns and survival in people with severe hemophilia A: real-world data from the Nordic hemostasis registry
Ali Moradi
Efficacy and safety of osiverol in adults with sickle cell disease: primary analysis of the phase 1b/2 ECLIPSE-2 study
Francesca Costa
Long-term outcomes of newly diagnosed transplant-eligible multiple myeloma treated with daratumumab, bortezomib, lenalidomide and dexamethasone: a French registry study of 87 patients
Astrid Gustafsson
Real-world effectiveness of olorofim in patients with invasive fungal infections: a multicenter dutch cohort
Olivier David
Health-related quality of life in NPM1-mutated AML: a prospective german study
Jessica Roberts
Ravelinib versus dasatinib in chronic-phase CML in deep molecular response (SAGA-2): a randomized phase 3 trial
Eva Friedrich
Prognostic value of vaso-occlusive crisis rate in patients with iron deficiency anemia: results from SAGA-6
Michael Zimmermann
Pathogen-reduced platelets versus patient blood management in preterm neonates (CORONA-8): a phase 1 trial
Sophie Berger
Circulating tumor dna predicts outcome in previously untreated follicular lymphoma
Hyun-woo Choi
Concivumab plus direct oral anticoagulants in hemophilia B: randomized phase 2 results of the NORDLYS-4 trial
Birgit Lehmann
Real-world effectiveness of talvetamab in relapsed/refractory multiple myeloma after three prior lines: a multicenter british cohort
Andrea Wagner
Prognostic value of TP53 status in relapsed or refractory large B-cell lymphoma: results from SUMMIT-1
Cristina D'Angelo
Prognostic value of NPM1 mutations in NPM1-mutated AML: results from SUMMIT-8
Marco Gentile
Nk-501 versus busulfan myeloablation in transfusion-dependent beta-thalassemia (PRISM-6): a phase 1b/2 trial
Julia Williams
Targeting inflammatory aging of the stem cell niche in normal and malignant hematopoiesis: preclinical evidence
Paolo Bianchi
Long-term outcomes of lower-risk MDS with transfusion-dependent anemia treated with azacitidine: a Nordic registry study of 812 patients
Anja Weber
Real-world effectiveness of menavostat in adults with newly diagnosed AML receiving intensive induction: a multicenter multinational cohort
Christian Lorenz
Health-related quality of life in treatment-naive CLL: a prospective british study
Bogdan Stan
Prognostic value of vaso-occlusive crisis rate in non-transfusion-dependent beta-thalassemia: results from SAGA-7
Wolfgang Meier
A large language model assistant compared with expert morphological review on bone marrow smears: a prospective multicenter evaluation
Ida Halvorsen
Telvostat versus erythropoiesis-stimulating agents in therapy-related MDS (ECLIPSE-6): a randomized phase 2 trial
Kazuki Sasaki
Efficacy and safety of epretamab in classic Hodgkin lymphoma: primary analysis of the randomized phase 2 HORIZON-2 study
Nuria Morales
Targeting iron overload and oxidative stress in hemoglobinopathies: preclinical evidence
Alexandre Laurent
A deep-learning cytomorphology model compared with standard diagnostic workup on bone marrow smears: a prospective multicenter evaluation
Despoina Georgiou
Efficacy and safety of mitazovat in non-transfusion-dependent beta-thalassemia: primary analysis of the randomized phase 2 PRISM-4 study
Sophie Dekker
Treatment patterns and survival in adults with newly diagnosed AML receiving intensive induction: real-world data from the multinational AML registry
Pauline Lambert
Prognostic value of early molecular response at 3 months in newly diagnosed chronic-phase CML: results from TRIDENT-6
Miriam Vogel
Treatment patterns and survival in triple-class exposed myeloma: real-world data from the Nordic myeloma registry
Alessandra Villa
Vaso-occlusive crisis rate predicts outcome in pyruvate kinase deficiency
Lucy Lewis
Real-world effectiveness of olorofim in patients with invasive fungal infections: a multicenter french cohort
Johanna Schmitt
Efficacy and safety of vedotalimab in haploidentical transplant recipients: primary analysis of the randomized phase 2 TRIDENT-5 study
Emily Walker
Treatment patterns and survival in fit patients with untreated CLL: real-world data from the Dutch CLL registry
Neta Barak
Prognostic value of MRD negativity after induction in adults with Philadelphia chromosome-positive ALL: results from CASCADE-6
Daniel Schulz
Menin-kmt2a dependency predicts outcome in older adults with secondary AML
Claudia Meier
Orvematinib versus imatinib in chronic-phase CML in deep molecular response (SAGA-3): a randomized phase 2 trial
Marie Hoffmann
Long-term outcomes of MDS with SF3B1 mutation treated with erythropoiesis-stimulating agents: a French registry study of 1240 patients
Florian Berger
Treatment patterns and survival in older patients with hematologic cancers: real-world data from the Nordic supportive care registry
Mathieu Girard
Real-world effectiveness of ravotuzumab vedotin in newly diagnosed AML patients ineligible for intensive chemotherapy: a multicenter nordic cohort
Silvia Leone
Efactocog beta versus low-molecular-weight heparin in patients with antiphospholipid syndrome (ARCTIC-4): a randomized phase 2 trial
Jana Novák
Ravotuzumab vedotin versus decitabine in older adults with secondary AML (CORONA-7): a randomized phase 2 trial
Magnus Haugen
Single-cell profiling reveals inflammatory aging of the stem cell niche in normal and malignant hematopoiesis
Johannes Weber
Real-world effectiveness of zelvudocel in adolescents and young adults with ALL: a multicenter multinational cohort
Klaus Hahn
Health-related quality of life in non-transfusion-dependent beta-thalassemia: a prospective italian study
Paola Rinaldi
Targeting immune effector cell-associated neurotoxicity in gene and cell therapy: preclinical evidence
Heidi Saarinen
Multi-omic characterization of graft-versus-leukemia effect in adults undergoing allogeneic stem cell transplantation for AML
Alba Molina
Etapivat versus hydroxyurea in non-transfusion-dependent beta-thalassemia (ARCTIC-7): a randomized phase 3 trial
James Edwards
Real-world effectiveness of exacatogene autotemcel in transfusion-dependent beta-thalassemia: a multicenter french cohort
Ida Olsen
Single-cell profiling reveals graft-versus-leukemia effect in allogeneic stem cell transplantation
Nuria Romero
Efficacy and safety of belosarib in patients with steroid-refractory acute graft-versus-host disease: primary analysis of the phase 1b/2 HORIZON-9 study
Hugo Lambert
Navolatib versus ruxolitinib in myelofibrosis after ruxolitinib failure (HELIOS-6): a randomized phase 3 trial
Raluca Ciobanu
Real-world effectiveness of concivumab in people with severe hemophilia A: a multicenter german cohort
Markus Schmidt
Abelorimab plus low-molecular-weight heparin in people with severe hemophilia A: phase 2 results of the ZENITH-5 trial
Vincent Laurent
Treatment patterns and survival in long-term survivors of childhood leukemia: real-world data from the Italian supportive care registry
Nikola Marković
Mrd negativity after induction predicts outcome in relapsed B-cell precursor ALL
Shota Takahashi
Efficacy and safety of zelvudocel in patients receiving CD19-directed CAR T-cell therapy: primary analysis of the phase 1 PRISM-5 study
Andreas Berger
Prognostic value of platelet count increment in preterm neonates: results from ZENITH-9
Yu Zhou
Targeting transfusion-related immunomodulation in transfusion practice: preclinical evidence
Theresa Becker
Prognostic value of patient-reported outcomes in older patients with hematologic cancers: results from TRIDENT-7
Élodie Guerin
Single-cell profiling reveals leukemic stem cell persistence in acute myeloid leukemia (AML)
Qing Wu
Prognostic value of high molecular risk mutations in myelofibrosis after ruxolitinib failure: results from PRISM-3
Thomas Nicolas
A large language model assistant compared with standard diagnostic workup on multicenter flow cytometry datasets: a prospective multicenter evaluation
Anne Richard
A federated learning platform compared with standard diagnostic workup on bone marrow smears: a prospective multicenter evaluation
Heidi Kinnunen
Ascavinib plus dasatinib in chronic-phase CML in deep molecular response: phase 3 results of the SUMMIT-8 trial
Pavel Novák
Treatment patterns and survival in people with severe hemophilia A: real-world data from the Italian hemostasis registry
Margaux Moreau
Efficacy and safety of pathogen-reduced platelets in patients with massive hemorrhage: primary analysis of the phase 3 MERIDIAN-9 study
Matteo Longo
Anicavocel versus carfilzomib and dexamethasone in triple-class exposed myeloma (VALOR-4): a randomized phase 3 trial
Georgia Papageorgiou
Hepcidin levels predicts outcome in adults with sickle cell disease
Florian Koch
Prognostic value of HSC quiescence markers in healthy donors: results from SAGA-6
Anna Schmidt
Bcr::abl1 transcript levels predicts outcome in chronic-phase CML in deep molecular response
Jonas Weber
Targeting clonal evolution under BCMA pressure in multiple myeloma: preclinical evidence
Lukas Scholz
Targeting endothelial activation in hemoglobinopathies: preclinical evidence
Matthew Moore
Multi-omic characterization of lineage priming in early progenitors in healthy donors
Guillaume Fournier
Treatment patterns and survival in older recipients of reduced-intensity conditioning: real-world data from the German allo-HSCT registry
Fernando Moreno
Real-world effectiveness of lirafenib in AML in first complete remission: a multicenter french cohort
Andrew Clark
Prognostic value of Ph-like signatures in relapsed B-cell precursor ALL: results from ATLAS-6
Amit Golan
Undetectable mrd predicts outcome in older patients with CLL and comorbidities
Beatrice Lombardo
Real-world effectiveness of ravelinib in chronic-phase CML in deep molecular response: a multicenter international cohort
Miguel González
Efficacy and safety of corvalimab in T-cell ALL: primary analysis of the phase 1b/2 ZENITH-9 study
Heather Allen
Hepcidin levels predicts outcome in adults with sickle cell disease
Luca Gallo
Multi-omic characterization of financial toxicity in long-term survivors of childhood leukemia
Silvia González
Vedotalimab plus tacrolimus and methotrexate in adults undergoing allogeneic stem cell transplantation for AML: phase 2 results of the ECLIPSE-4 trial
Despoina Papageorgiou
Single-cell profiling reveals immune effector cell-associated neurotoxicity in gene and cell therapy
Sara Eriksson
Long-term outcomes of patients with steroid-refractory acute graft-versus-host disease treated with post-transplant cyclophosphamide: a international registry study of 2105 patients
Samir Nasser
Inclazumab plus hydroxyurea in non-transfusion-dependent beta-thalassemia: phase 2 results of the TRIDENT-6 trial
Hugo Silva
Concivumab plus direct oral anticoagulants in cancer-associated venous thromboembolism: phase 3 results of the BEACON-3 trial
Ionuț Popa
Treatment patterns and survival in NPM1-mutated AML: real-world data from the Dutch AML registry
Sarah Roth
Efficacy and safety of etapivat in non-transfusion-dependent beta-thalassemia: primary analysis of the randomized phase 2 ZENITH-7 study
Nicole Becker
Tamirodene versus azacitidine in MDS with SF3B1 mutation (PRISM-5): a randomized phase 3 trial
Tim Dijkstra
Hepcidin levels predicts outcome in non-transfusion-dependent beta-thalassemia
Jonathan Morris
Prognostic value of patient-reported outcomes in older patients with hematologic cancers: results from NORDLYS-5
Joost Peters
Donor-specific antibodies predicts outcome in older recipients of reduced-intensity conditioning
Claire Bennett
Brexalucel plus Pola-R-CHP in classic Hodgkin lymphoma: randomized phase 2 results of the CORONA-9 trial
Thomas Becker
Ravelinib plus nilotinib in chronic-phase CML in deep molecular response: phase 1b/2 results of the VIKING-6 trial
Iris Kok
A digital symptom-monitoring program plus standard supportive care in patients with invasive fungal infections: phase 2 results of the ARCTIC-1 trial
Jürgen Schulz
Multi-omic characterization of inflammatory aging of the stem cell niche in patients with clonal hematopoiesis of indeterminate potential
Dana Rosenberg
Efficacy and safety of rilvabrutinib in people with severe hemophilia A: primary analysis of the randomized phase 3 ECLIPSE-1 study
Gabriela Nascimento
Treatment patterns and survival in older recipients of reduced-intensity conditioning: real-world data from the international allo-HSCT registry
Pierre Bertrand
Efficacy and safety of belosarib in adults undergoing allogeneic stem cell transplantation for AML: primary analysis of the phase 3 POLARIS-9 study
Tamás Kiss
Long-term outcomes of lower-risk MDS with transfusion-dependent anemia treated with luspatercept: a Spanish registry study of 87 patients
Fatma Özkan
Multi-omic characterization of neutrophil extracellular traps in thrombosis in people with severe hemophilia A
André Jesus
Multi-omic characterization of endothelial activation in patients with iron deficiency anemia
Hui Wang
A federated learning platform compared with expert morphological review on routine blood counts in primary care: a prospective multicenter evaluation
Hugo Roussel
Hsc quiescence markers predicts outcome in aged mice
Ming Gao
A deep-learning cytomorphology model compared with standard diagnostic workup on bone marrow smears: a prospective multicenter evaluation
Signe Møller
Long-term outcomes of older adults with secondary AML treated with decitabine: a British registry study of 304 patients
Alexander Walker
A deep-learning cytomorphology model compared with standard diagnostic workup on bone marrow smears: a prospective multicenter evaluation
Tarik Kovačević
Real-world effectiveness of cold-stored platelets in patients undergoing cardiac surgery: a multicenter spanish cohort
Ana Alves
Prognostic value of annualized bleeding rate in cancer-associated venous thromboembolism: results from BEACON-8
Daniel Nelson
Treatment patterns and survival in newly diagnosed transplant-eligible multiple myeloma: real-world data from the Italian myeloma registry
Christina Weiß
Factor viii activity predicts outcome in adults with immune thrombocytopenia
Fernando Ortega
Calr mutations predicts outcome in JAK inhibitor-naive myelofibrosis
Haruka Kobayashi
Validation of a federated learning platform for automated classification of bone marrow cells across 55 centers
Maximilian Baumann
Mitazovat versus chronic transfusion in patients with iron deficiency anemia (VIKING-2): a phase 3 trial
Tomasz Wójcik
Orvematinib versus dasatinib in newly diagnosed chronic-phase CML (HORIZON-8): a randomized phase 2 trial
Élodie Morel
Targeting tissue factor pathway regulation in bleeding and thrombotic disorders: preclinical evidence
Jan Schmidt
Targeting lineage priming in early progenitors in normal and malignant hematopoiesis: preclinical evidence
Ming Guo
Efficacy and safety of ravotuzumab vedotin in NPM1-mutated AML: primary analysis of the phase 2 POLARIS-9 study
Camila Ferreira
Pathogen-reduced platelets versus restrictive transfusion thresholds in patients undergoing cardiac surgery (ATLAS-4): a phase 2 trial
Émilie François
Itovazumab plus anti-thymocyte globulin in adults undergoing allogeneic stem cell transplantation for AML: phase 2 results of the ALTITUDE-4 trial
Amelia Clarke
Treatment patterns and survival in patients receiving CAR T-cell therapy: real-world data from the German supportive care registry
Sarah Morris
Treatment patterns and survival in patients with steroid-refractory acute graft-versus-host disease: real-world data from the Spanish allo-HSCT registry
Stefan de Wit
Multi-omic characterization of steroid resistance pathways in T-cell ALL
Elin Nyström
Long-term outcomes of primary CNS lymphoma treated with CAR T-cell therapy: a French registry study of 812 patients
Bo Ma
Single-cell profiling reveals clonal evolution at relapse in acute myeloid leukemia (AML)
Marie Günther
Long-term outcomes of essential thrombocythemia treated with ropeginterferon alfa-2b: a Dutch registry study of 304 patients
Ana Gómez
Momavotinib plus ruxolitinib in JAK inhibitor-naive myelofibrosis: randomized phase 3 results of the MERIDIAN-3 trial
Michael Hofmann
Multi-omic characterization of clonal evolution at relapse in older adults with secondary AML
Moritz Wolf
Efficacy and safety of marsatimab in people with severe hemophilia A: primary analysis of the randomized phase 2 ATLAS-4 study
Élodie Thomas
Efficacy and safety of inclazumab in pyruvate kinase deficiency: primary analysis of the phase 1 HELIOS-4 study
Yu Lin
Single-cell profiling reveals epigenetic memory after infection in normal and malignant hematopoiesis
Jonas Schwarz
Vedotalimab versus tacrolimus and methotrexate in adults undergoing allogeneic stem cell transplantation for AML (TRIDENT-6): a phase 1 trial
Elena Smirnov
Efficacy and safety of whole blood in blood donors: primary analysis of the randomized phase 3 HORIZON-7 study
Kavya Reddy
A federated learning platform compared with standard diagnostic workup on routine blood counts in primary care: a prospective multicenter evaluation
Layla Hamdan
Marsatimab plus low-molecular-weight heparin in people with severe hemophilia A: phase 2 results of the MERIDIAN-3 trial
Birgit Hofmann
Long-term outcomes of polycythemia vera treated with hydroxyurea: a multinational registry study of 58 patients
Wolfgang Weiß
Targeting lineage priming in early progenitors in normal and malignant hematopoiesis: preclinical evidence
Eva Braun
Itovazumab versus anti-thymocyte globulin in patients with steroid-refractory acute graft-versus-host disease (VIKING-4): a randomized phase 2 trial
Hala Mahmoud
Long-term outcomes of preterm neonates treated with restrictive transfusion thresholds: a international registry study of 188 patients
Johanna Richter
Prognostic value of TP53 mutations in NPM1-mutated AML: results from TRIDENT-3
Manuel Romero
Validation of a federated learning platform for early detection of acute leukemia across 4 centers
Alexandru Dumitru
Treatment patterns and survival in CML after two or more tyrosine kinase inhibitors: real-world data from the international CML registry
Mikkel Poulsen
Efficacy and safety of odrolimab in primary CNS lymphoma: primary analysis of the phase 1b/2 ALTITUDE-7 study
Qing Liu
Ferritin in donors predicts outcome in preterm neonates
Bram van den Berg
Targeting immune effector cell-associated neurotoxicity in gene and cell therapy: preclinical evidence
Priya Chatterjee
Letermovir versus antifungal prophylaxis in patients with invasive fungal infections (VALOR-4): a phase 1 trial
Alexander Hartmann
Undetectable mrd predicts outcome in relapsed CLL after covalent BTK inhibitors
Yossi Goldberg
Long-term outcomes of adults undergoing allogeneic stem cell transplantation for AML treated with anti-thymocyte globulin: a German registry study of 304 patients
Axel Sjöberg
Real-world effectiveness of whole blood in patients with massive hemorrhage: a multicenter dutch cohort
Carolin Vogel
Treatment patterns and survival in fit patients with untreated CLL: real-world data from the German CLL registry
Theresa Winkler
Targeting inflammatory aging of the stem cell niche in normal and malignant hematopoiesis: preclinical evidence
Daniel Schneider
Efficacy and safety of ravelinib in newly diagnosed chronic-phase CML: primary analysis of the phase 1 HELIOS-1 study
Emi Suzuki
Svx-12 plus ibrutinib in fit patients with untreated CLL: phase 1 results of the AURORA-4 trial
Can Öztürk
Real-world effectiveness of SVX-12 in treatment-naive CLL: a multicenter nordic cohort
Andrew Thomas
Prognostic value of CALR mutations in myelofibrosis with anemia: results from HORIZON-5
Serena Gentile
Tovaclax plus venetoclax and obinutuzumab in CLL with del(17p) or TP53 mutation: phase 1 results of the SAGA-6 trial
Daniel Smith
Prognostic value of CMV reactivation in patients with steroid-refractory acute graft-versus-host disease: results from VIKING-2
Miriam Roth
Real-world effectiveness of mitazovat in adults with sickle cell disease: a multicenter german cohort
Andreas Günther
Etapivat versus hydroxyurea in non-transfusion-dependent beta-thalassemia (PRISM-4): a randomized phase 3 trial
Stefanie Zimmermann
Long-term outcomes of newly diagnosed transplant-eligible multiple myeloma treated with autologous stem cell transplantation: a multinational registry study of 87 patients
Jan Meier
Prognostic value of SF3B1 mutations in therapy-related MDS: results from ATLAS-6
David López
Validation of a deep-learning cytomorphology model for automated classification of bone marrow cells across 52 centers
Heather Turner
Multi-omic characterization of epigenetic memory after infection in human cord blood
Sophie Fischer
Inclazumab versus hydroxyurea in patients with iron deficiency anemia (HELIOS-8): a randomized phase 2 trial
Maxime Faure
Treatment patterns and survival in patients with antiphospholipid syndrome: real-world data from the French hemostasis registry
Elena Moreno
Targeting inflammatory aging of the stem cell niche in normal and malignant hematopoiesis: preclinical evidence
Laura King
A federated learning platform compared with expert morphological review on bone marrow smears: a prospective multicenter evaluation
Elisa Gentile
Real-world effectiveness of zelvudocel in adults with Philadelphia chromosome-positive ALL: a multicenter nordic cohort
Robert Allen
Letermovir plus standard supportive care in patients receiving CAR T-cell therapy: randomized phase 2 results of the TRIDENT-4 trial
Rocío Romero
Ikzf1 deletions predicts outcome in T-cell ALL
Álvaro Ramírez
D-dimer predicts outcome in adults with immune thrombocytopenia
Tobias Schulz
Telvostat plus azacitidine in lower-risk MDS with transfusion-dependent anemia: phase 1b/2 results of the TRIDENT-1 trial
Jürgen Baumann
Targeting ineffective erythropoiesis in myelodysplastic syndromes (MDS): preclinical evidence
Rachel Evans
Prognostic value of platelet count increment in preterm neonates: results from ATLAS-2
Allison Wilson
Real-world effectiveness of quelcitamab in newly diagnosed AML patients ineligible for intensive chemotherapy: a multicenter spanish cohort
Lotte van Dijk
Long-term outcomes of adults with sickle cell disease treated with chronic transfusion: a Italian registry study of 87 patients
Sophie Keller
Prognostic value of IGHV mutational status in older patients with CLL and comorbidities: results from CORONA-1
Sabine Berger
Menavostat versus decitabine in relapsed or refractory FLT3-mutated AML (ALTITUDE-8): a randomized phase 3 trial
Saeed Mohammadi
Real-world effectiveness of letermovir in older patients with hematologic cancers: a multicenter german cohort
Rocío Blanco
Treatment patterns and survival in adults with newly diagnosed AML receiving intensive induction: real-world data from the Dutch AML registry
Birgit Vogel
Treatment patterns and survival in AML in first complete remission: real-world data from the French AML registry
Gustavo Ribeiro
Targeting transfusion-related immunomodulation in transfusion practice: preclinical evidence
Sébastien Lambert
Platelet count increment predicts outcome in preterm neonates
Pietro Mancini
Multi-omic characterization of BCR signalling rewiring in CLL with del(17p) or TP53 mutation
Paolo Costa
Prognostic value of infection-related mortality in patients with invasive fungal infections: results from MERIDIAN-3
Christina Makris
Long-term outcomes of mantle cell lymphoma after BTK inhibitor failure treated with bendamustine and rituximab: a Nordic registry study of 412 patients
Wolfgang Müller
Health-related quality of life in myelofibrosis with anemia: a prospective german study
Johannes Wolf
Calr mutations predicts outcome in myelofibrosis with anemia
Sébastien Garnier
Hsc quiescence markers predicts outcome in healthy donors
María Ramos
Multi-omic characterization of epigenetic memory after infection in aged mice
Rodrigo Nascimento
Efficacy and safety of ascavinib in CML after two or more tyrosine kinase inhibitors: primary analysis of the phase 2 ZENITH-1 study
Simone De Luca
Alloimmunization predicts outcome in patients with massive hemorrhage
Renata Nascimento
Menin-kmt2a dependency predicts outcome in NPM1-mutated AML
Lars de Graaf
Prognostic value of measurable residual disease by flow cytometry in adults with newly diagnosed AML receiving intensive induction: results from VALOR-6
Miriam Huber
Efficacy and safety of momavotinib in essential thrombocythemia: primary analysis of the randomized phase 3 PRISM-5 study
Benoît Morel
Belosarib plus tacrolimus and methotrexate in adults undergoing allogeneic stem cell transplantation for AML: randomized phase 3 results of the CASCADE-9 trial
Bram van der Linden
Prognostic value of early chimerism in older recipients of reduced-intensity conditioning: results from SUMMIT-3
Rasmus Nielsen
Hepcidin levels predicts outcome in adults with sickle cell disease
Lucy Wilson
Single-cell profiling reveals quiescent CML stem cells in chronic myeloid leukemia (CML)
Lukáš Novotný
Itovazumab versus anti-thymocyte globulin in patients with steroid-refractory acute graft-versus-host disease (VIKING-7): a phase 2 trial
Anna Farkas
Treatment patterns and survival in patients with iron deficiency anemia: real-world data from the Dutch SCD registry
Sanna Korhonen
Targeting red cell storage lesion in transfusion practice: preclinical evidence
Fang Yang
Health-related quality of life in cancer-associated venous thromboembolism: a prospective spanish study
François Lefebvre
Long-term outcomes of recipients of allogeneic off-the-shelf CAR NK cells treated with busulfan myeloablation: a British registry study of 412 patients
Emma Hughes
Ibrexitamab plus pediatric-inspired chemotherapy in adults with Philadelphia chromosome-positive ALL: phase 1 results of the MERIDIAN-1 trial
Bin Liu
Efficacy and safety of NK-501 in patients with sickle cell disease treated with gene editing: primary analysis of the randomized phase 2 POLARIS-7 study
Valentina Costa
Efficacy and safety of rusperatide in JAK inhibitor-naive myelofibrosis: primary analysis of the phase 3 ZENITH-2 study
Thijs de Jong
Targeting gut epithelial injury in GVHD in allogeneic stem cell transplantation: preclinical evidence
Esther Meijer
Validation of a large language model assistant for early detection of acute leukemia across 9 centers
Nicole Fischer
Real-world effectiveness of a digital symptom-monitoring program in long-term survivors of childhood leukemia: a multicenter nordic cohort
Anna Vitale
Single-cell profiling reveals treatment burden in hematologic malignancies
Alessandro D'Angelo
A deep-learning cytomorphology model compared with standard diagnostic workup on bone marrow smears: a prospective multicenter evaluation
Jian Wu
Osiverol versus iron chelation in adults with sickle cell disease (TRIDENT-7): a phase 1 trial
Ida Hansen
Belosarib versus anti-thymocyte globulin in haploidentical transplant recipients (VIKING-2): a phase 3 trial
Jessica Taylor
Vaso-occlusive crisis rate predicts outcome in patients with iron deficiency anemia
Jessica Hill
Real-world effectiveness of belosarib in haploidentical transplant recipients: a multicenter international cohort
Sanjay Kumar
Efficacy and safety of pirvabrutinib in relapsed CLL after covalent BTK inhibitors: primary analysis of the phase 1 VALOR-9 study
Alexandre Guerin
Long-term outcomes of patients with massive hemorrhage treated with restrictive transfusion thresholds: a Italian registry study of 188 patients
Fang Liu
Prognostic value of BCMA soluble levels in relapsed/refractory multiple myeloma after three prior lines: results from MERIDIAN-6
Anja Keller
Long-term outcomes of older recipients of reduced-intensity conditioning treated with post-transplant cyclophosphamide: a international registry study of 64 patients
Markus Jung
Calr mutations predicts outcome in polycythemia vera
Miguel Lopes
Single-cell profiling reveals immune reconstitution after bispecific antibodies in multiple myeloma
Andrea Wolf
Health-related quality of life in relapsed CLL after covalent BTK inhibitors: a prospective european study
Carolin Fischer
Abl1 kinase domain mutations predicts outcome in chronic-phase CML in deep molecular response
Kenji Takahashi
Cold-stored platelets plus restrictive transfusion thresholds in patients with massive hemorrhage: randomized phase 2 results of the ARCTIC-7 trial
Lukas Peters
Treatment patterns and survival in patients with antiphospholipid syndrome: real-world data from the European hemostasis registry
Ilaria Coppola
Efficacy and safety of ponavatinib in adolescents and young adults with ALL: primary analysis of the phase 3 ATLAS-5 study
Xiaoyan Liu
Health-related quality of life in adults with sickle cell disease: a prospective international study
Christian Beck
Cell-of-origin subtype predicts outcome in classic Hodgkin lymphoma
Gil Golan
Single-cell profiling reveals T-cell exhaustion in CLL in chronic lymphocytic leukemia (CLL)
Marta Kwiatkowski
Health-related quality of life in older recipients of reduced-intensity conditioning: a prospective spanish study
Paolo Mariani
Prognostic value of complex karyotype in relapsed CLL after covalent BTK inhibitors: results from ZENITH-2
Jonas Weiß
Targeting epigenetic memory after infection in normal and malignant hematopoiesis: preclinical evidence
Charlotte Murray
A federated learning platform compared with expert morphological review on bone marrow smears: a prospective multicenter evaluation
Stefanie Klein
Long-term outcomes of myelofibrosis with anemia treated with hydroxyurea: a German registry study of 112 patients
Lea Schulz
Prognostic value of clonal hematopoiesis in adults with newly diagnosed AML receiving intensive induction: results from POLARIS-2
Lea Braun
Sf3b1 mutations predicts outcome in higher-risk MDS
Liang Wang
Inclazumab plus hydroxyurea in children with sickle cell disease in sub-Saharan Africa: phase 3 results of the ECLIPSE-6 trial
Paweł Kamiński
Health-related quality of life in treatment-naive CLL: a prospective international study
Henry Campbell
Health-related quality of life in adults with sickle cell disease: a prospective european study
Matteo Martini
Ravelinib plus nilotinib in chronic-phase CML in deep molecular response: randomized phase 3 results of the VALOR-4 trial
Paula Torres
Zelvudocel versus blinatumomab in adults with Philadelphia chromosome-positive ALL (ECLIPSE-2): a phase 1b/2 trial
Hüseyin Kılıç
Prognostic value of spleen volume reduction in myelofibrosis with anemia: results from VIKING-3
Frederik Madsen
Treatment patterns and survival in treatment-naive CLL: real-world data from the multinational CLL registry
Joost Dijkstra
A deep-learning cytomorphology model compared with expert morphological review on multicenter flow cytometry datasets: a prospective multicenter evaluation
Johannes Huber
Prognostic value of TP53 status in classic Hodgkin lymphoma: results from HORIZON-3
Katharina Huber
Targeting T-cell exhaustion in CLL in chronic lymphocytic leukemia (CLL): preclinical evidence
Ying Hu
Pirvabrutinib plus acalabrutinib in CLL with del(17p) or TP53 mutation: phase 1b/2 results of the SAGA-4 trial
Ioannis Michailidis
Tozarinib plus cytarabine and daunorubicin in adults with newly diagnosed AML receiving intensive induction: randomized phase 2 results of the SUMMIT-6 trial
Maya Ofer
Single-cell profiling reveals tumour microenvironment remodelling in lymphoma
Miriam Berger
Multi-omic characterization of steroid resistance pathways in adults with Philadelphia chromosome-positive ALL
Layla Aziz
A federated learning platform compared with expert morphological review on bone marrow smears: a prospective multicenter evaluation
Mark Walker
Ascavinib versus nilotinib in newly diagnosed chronic-phase CML (TRIDENT-1): a randomized phase 2 trial
Omer Levi
Multi-omic characterization of red cell storage lesion in preterm neonates
Jonas Fuchs
D-dimer predicts outcome in hemophilia B
Marta Marino
Orvematinib versus nilotinib in CML after two or more tyrosine kinase inhibitors (TRIDENT-8): a phase 2 trial
Andrea Fontana
Nk-501 plus lymphodepletion with fludarabine and cyclophosphamide in patients receiving CD19-directed CAR T-cell therapy: phase 3 results of the POLARIS-6 trial
Mihai Dumitru
Prognostic value of undetectable MRD in older patients with CLL and comorbidities: results from ALTITUDE-1
Florian Lange
Mitazovat plus hydroxyurea in non-transfusion-dependent beta-thalassemia: randomized phase 2 results of the AURORA-3 trial
Stefan Meijer
Single-cell profiling reveals tumour microenvironment remodelling in lymphoma
James Bennett
Efficacy and safety of a digital symptom-monitoring program in long-term survivors of childhood leukemia: primary analysis of the randomized phase 2 TRIDENT-3 study
Daniel Meier
Multi-omic characterization of treatment-free remission biology in chronic-phase CML in deep molecular response
Martin Lorenz
Multi-omic characterization of lineage switch after CD19-directed therapy in relapsed B-cell precursor ALL
Na Zhao
Abl1 kinase domain mutations predicts outcome in chronic-phase CML in deep molecular response
Stefanie Lorenz
Ighv mutational status predicts outcome in older patients with CLL and comorbidities
Akiko Inoue
Single-cell profiling reveals inflammatory aging of the stem cell niche in normal and malignant hematopoiesis
Federico Marino
Efficacy and safety of tamirodene in therapy-related MDS: primary analysis of the phase 3 SUMMIT-1 study
Jason Clark
Navolatib plus ruxolitinib in essential thrombocythemia: phase 1b/2 results of the MERIDIAN-6 trial
Lukas Wagner
Belosarib plus post-transplant cyclophosphamide in older recipients of reduced-intensity conditioning: phase 3 results of the ALTITUDE-7 trial
Camilla Johansen
Multi-omic characterization of immune evasion in the bone marrow niche in newly diagnosed AML patients ineligible for intensive chemotherapy
Marie Weber
Efficacy and safety of NK-501 in recipients of allogeneic off-the-shelf CAR NK cells: primary analysis of the randomized phase 2 ALTITUDE-3 study
Beatrice Rinaldi
Zelvudocel versus tyrosine kinase inhibitors in children with high-risk B-cell ALL (BEACON-5): a phase 3 trial
James Morris
Health-related quality of life in AL amyloidosis: a prospective dutch study
Elena Marchetti
Real-world effectiveness of brexalucel in relapsed or refractory large B-cell lymphoma: a multicenter nordic cohort
Georgios Karagiannis
Targeting immune effector cell-associated neurotoxicity in gene and cell therapy: preclinical evidence
Rocío Martín
Single-cell profiling reveals inflammatory aging of the stem cell niche in normal and malignant hematopoiesis
Álvaro Sánchez
Multi-omic characterization of tissue factor pathway regulation in cancer-associated venous thromboembolism
Marie Meyer
Real-world effectiveness of tamirodene in therapy-related MDS: a multicenter nordic cohort
Tobias Bauer
Multi-omic characterization of neutrophil extracellular traps in thrombosis in cancer-associated venous thromboembolism
Feng Guo
Treatment patterns and survival in newly diagnosed transplant-eligible multiple myeloma: real-world data from the Spanish myeloma registry
Carolin Scholz
Targeting transfusion-related immunomodulation in transfusion practice: preclinical evidence
Laura Patel
Health-related quality of life in older recipients of reduced-intensity conditioning: a prospective british study
Sergio Fernández
Efficacy and safety of NK-501 in patients receiving CD19-directed CAR T-cell therapy: primary analysis of the phase 3 ARCTIC-8 study
Katharina Braun
Single-cell profiling reveals inflammatory aging of the stem cell niche in normal and malignant hematopoiesis
Takuya Shimizu
Real-world effectiveness of inclazumab in non-transfusion-dependent beta-thalassemia: a multicenter multinational cohort
Ilaria Gentile
Targeting inflammatory aging of the stem cell niche in normal and malignant hematopoiesis: preclinical evidence
Mehmet Koç
Long-term outcomes of adults with Philadelphia chromosome-positive ALL treated with tyrosine kinase inhibitors: a Dutch registry study of 146 patients
Hannah Braun
Ponavatinib plus tyrosine kinase inhibitors in adolescents and young adults with ALL: phase 1b/2 results of the CASCADE-9 trial
Javier Gutiérrez
Prognostic value of ferritin in donors in patients with massive hemorrhage: results from TRIDENT-5
Stefanie Neumann
Prognostic value of inflammatory memory in healthy donors: results from ZENITH-8
Beatriz Marín
Treatment patterns and survival in triple-class exposed myeloma: real-world data from the international myeloma registry
Hao Yang
Long-term outcomes of chronic-phase CML in deep molecular response treated with imatinib: a Dutch registry study of 188 patients
Jürgen Möller
Single-cell profiling reveals leukemic stem cell persistence in acute myeloid leukemia (AML)
Selin Öztürk
Validation of a federated learning platform for automated classification of bone marrow cells across 15 centers
Alexander Zimmermann
A federated learning platform compared with standard diagnostic workup on multicenter flow cytometry datasets: a prospective multicenter evaluation
John Wright
Single-cell profiling reveals inflammatory aging of the stem cell niche in normal and malignant hematopoiesis
Andrea Krüger
Ascavinib versus nilotinib in newly diagnosed chronic-phase CML (PRISM-9): a phase 2 trial
Lin Lin
Targeting editing efficiency in long-term HSC in gene and cell therapy: preclinical evidence
Frank Baumann
Treatment patterns and survival in cancer-associated venous thromboembolism: real-world data from the Nordic hemostasis registry
Matthew Martin
Efficacy and safety of sabrelimab in therapy-related MDS: primary analysis of the phase 3 SUMMIT-5 study
Rachel Mitchell
Efficacy and safety of tovaclax in treatment-naive CLL: primary analysis of the phase 2 SAGA-4 study
Piotr Kaczmarek
Ibrexitamab versus pediatric-inspired chemotherapy in adolescents and young adults with ALL (ECLIPSE-1): a randomized phase 3 trial
Xiaoyan Ma
Single-cell profiling reveals epigenetic memory after infection in normal and malignant hematopoiesis
Eva Schwarz
Efficacy and safety of nelbrutinib in older patients with CLL and comorbidities: primary analysis of the randomized phase 3 CORONA-7 study
Isabelle Richard
Multi-omic characterization of inflammatory aging of the stem cell niche in aged mice
Ali Khoury
Prognostic value of MRD negativity at 10^-6 in AL amyloidosis: results from AURORA-7
Julien Bernard
Prognostic value of early molecular response at 3 months in chronic-phase CML in deep molecular response: results from HORIZON-3
Anna Friedrich
Navolatib versus hydroxyurea in myelofibrosis with anemia (VIKING-5): a randomized phase 3 trial
Claudio Ferrara
Prognostic value of vector copy number in recipients of allogeneic off-the-shelf CAR NK cells: results from NORDLYS-2
Birgit Hahn
Lisarnetamab versus bendamustine and rituximab in classic Hodgkin lymphoma (CASCADE-9): a randomized phase 3 trial
Felix Peters
A large language model assistant compared with expert morphological review on multicenter flow cytometry datasets: a prospective multicenter evaluation
Juliana Silva
Treatment patterns and survival in AML in first complete remission: real-world data from the German AML registry
Georgios Angelopoulos
Health-related quality of life in triple-class exposed myeloma: a prospective european study
Stefan Weiß
Prognostic value of CALR mutations in polycythemia vera: results from PRISM-7
Stefan Krüger
Multi-omic characterization of leukemic stem cell persistence in older adults with secondary AML
Bogdan Ciobanu
Ibarodomide versus autologous stem cell transplantation in newly diagnosed transplant-eligible multiple myeloma (CORONA-3): a randomized phase 2 trial
Francesco De Santis
Single-cell profiling reveals clonal evolution under BCMA pressure in multiple myeloma
Ulrike Neumann
A large language model assistant compared with standard diagnostic workup on bone marrow smears: a prospective multicenter evaluation
Sarah Ward
Treatment patterns and survival in patients with massive hemorrhage: real-world data from the Dutch transfusion registry
Robert Hughes
Health-related quality of life in CML after two or more tyrosine kinase inhibitors: a prospective nordic study
Burak Kılıç
Targeting treatment burden in hematologic malignancies: preclinical evidence
Thomas Klein
Platelet count increment predicts outcome in preterm neonates
Aikaterini Angelopoulos
Validation of a federated learning platform for automated classification of bone marrow cells across 29 centers
Marta Villa
Single-cell profiling reveals epigenetic memory after infection in normal and malignant hematopoiesis
Mikkel Thomsen
High-risk cytogenetics predicts outcome in high-risk smoldering myeloma
Carolin Zimmermann
Real-world effectiveness of cold-stored platelets in patients undergoing cardiac surgery: a multicenter international cohort
Morten Hansen
Inflammatory memory predicts outcome in human cord blood
Laura Schmitt
Exacatogene autotemcel plus busulfan myeloablation in transfusion-dependent beta-thalassemia: phase 1b/2 results of the VIKING-3 trial
Bin Ma
Patient-reported outcomes predicts outcome in patients receiving CAR T-cell therapy
Khaled Nasser
Treatment patterns and survival in patients with antiphospholipid syndrome: real-world data from the Spanish hemostasis registry
Marie Müller
Olorofim versus antifungal prophylaxis in patients with invasive fungal infections (HELIOS-4): a phase 1 trial
Noam Avraham
A deep-learning cytomorphology model compared with standard diagnostic workup on routine blood counts in primary care: a prospective multicenter evaluation
Bogdan Munteanu
Concivumab plus thrombopoietin receptor agonists in adults with immune thrombocytopenia: phase 2 results of the ATLAS-6 trial
Gang Zhang
Itovazumab versus post-transplant cyclophosphamide in haploidentical transplant recipients (TRIDENT-8): a phase 2 trial
Marie Moreau
Health-related quality of life in patients receiving CAR T-cell therapy: a prospective british study
Oliver Smith
Prognostic value of clonal hematopoiesis in newly diagnosed AML patients ineligible for intensive chemotherapy: results from BEACON-6
Charlotte Smith
Measurable residual disease by flow cytometry predicts outcome in AML in first complete remission
Christian Jung
Multi-omic characterization of inflammatory aging of the stem cell niche in aged mice
Jing Huang
Targeting inflammatory aging of the stem cell niche in normal and malignant hematopoiesis: preclinical evidence
Layla Saad
Single-cell profiling reveals financial toxicity in hematologic malignancies
Christina Karagiannis
Prognostic value of annualized bleeding rate in hemophilia B: results from AURORA-3
Christopher Baker
Treatment patterns and survival in older patients with hematologic cancers: real-world data from the Spanish supportive care registry
Megan Martin
Letermovir versus antifungal prophylaxis in patients receiving CAR T-cell therapy (ECLIPSE-5): a phase 1b/2 trial
Katharina Scholz
Efficacy and safety of pelarisib in myelofibrosis after ruxolitinib failure: primary analysis of the randomized phase 3 HELIOS-9 study
Marie Vogel
Validation of a federated learning platform for automated classification of bone marrow cells across 42 centers
Christos Alexiou
Svx-12 versus venetoclax and obinutuzumab in older patients with CLL and comorbidities (SAGA-6): a phase 2 trial
Andrea Gallo
Treatment patterns and survival in pyruvate kinase deficiency: real-world data from the Dutch SCD registry
Alice Ward
Long-term outcomes of patients undergoing cardiac surgery treated with restrictive transfusion thresholds: a Nordic registry study of 304 patients
Thomas Scholz
Targeting financial toxicity in hematologic malignancies: preclinical evidence
Jan Braun
Menin-kmt2a dependency predicts outcome in relapsed or refractory FLT3-mutated AML
Moritz Hartmann
Real-world effectiveness of tamirodene in MDS with SF3B1 mutation: a multicenter spanish cohort
Chen Hu
Real-world effectiveness of epretamab in classic Hodgkin lymphoma: a multicenter french cohort
Bas van den Berg
Prognostic value of clonal hematopoiesis in NPM1-mutated AML: results from VIKING-6
Álvaro Fernández
Health-related quality of life in essential thrombocythemia: a prospective french study
Lukas Lorenz
Real-world effectiveness of vedotalimab in haploidentical transplant recipients: a multicenter multinational cohort
Eva Lange
Treatment patterns and survival in triple-class exposed myeloma: real-world data from the Dutch myeloma registry
Hui Zhang
Exacatogene autotemcel versus lymphodepletion with fludarabine and cyclophosphamide in patients receiving CD19-directed CAR T-cell therapy (CASCADE-2): a phase 2 trial
Brian Edwards
Interferon in polycythemia vera
Gang Gao
Myeloproliferative neoplasms: diagnosis and risk assessment
Ana Costa
Myeloproliferative neoplasms: long-term follow-up
Anders Poulsen
Patient blood management in 2023
William Jackson
Transfusion medicine: first-line treatment
Miriam Schröder
Transfusion medicine: first-line treatment
John Edwards
Fixed-duration versus continuous therapy in CLL
Anna Lehmann
Chronic lymphocytic leukemia: first-line treatment
Akiko Kimura
Chronic lymphocytic leukemia: long-term follow-up
Johannes Schmitt
Quadruplet induction for newly diagnosed myeloma
Alejandro Torres
Myeloma and plasma cell disorders: controversies and case discussion
Martin Keller
Myeloma and plasma cell disorders: first-line treatment
Luca Vitale
Late effects after childhood ALL
Brian Wilson
Acute lymphoblastic leukemia: managing relapse
Rahul Patel
Acute lymphoblastic leukemia: first-line treatment
Dimitrios Makris
Artificial intelligence in the hematology laboratory
Martina Rinaldi
Novel technologies and AI: emerging therapies
Camilla Kristensen
Novel technologies and AI: managing relapse
Takuya Kato
Primary CNS lymphoma
Jessica Turner
Lymphoma: managing relapse
Antonio Bianco
Lymphoma: managing relapse
Henrik Bakken
Non-factor therapies in hemophilia
Ece Şimşek
Bleeding, thrombosis and platelets: controversies and case discussion
Daniel Brown
Bleeding, thrombosis and platelets: diagnosis and risk assessment
Marie Winkler
Survivorship care after hematologic cancer
Tamás Kovács
Supportive care and quality of life: managing relapse
Klaus Fuchs
Supportive care and quality of life: emerging therapies
Bram Vos
IPSS-M in daily practice
Jelena Jurić
Myelodysplastic syndromes: long-term follow-up
Thomas Schulz
Myelodysplastic syndromes: diagnosis and risk assessment
Fabio Martini
Maintenance after allogeneic transplantation
Sophie Hahn
Stem cell transplantation: long-term follow-up
Petr Kučera
Stem cell transplantation: long-term follow-up
Alexander Müller
Treatment-free remission in CML: who, when and how
Óscar Hernández
Chronic myeloid leukemia: controversies and case discussion
Lena Schwarz
Chronic myeloid leukemia: first-line treatment
Ante Marković
Supportive care and quality of life: consensus recommendations
Alba Molina
Supportive care and quality of life: European registries and collaboration
Martin Vogel
Supportive care and quality of life: what is new in the clinic
André Santos
Stem cell transplantation: consensus recommendations
Matthew Taylor
Stem cell transplantation: European registries and collaboration
Richard Brown
Stem cell transplantation: state of the art
David Brown
Acute lymphoblastic leukemia: what is new in the clinic
Manuel Rodríguez
Acute lymphoblastic leukemia: European registries and collaboration
Elisa Galli
Acute lymphoblastic leukemia: consensus recommendations
Leonardo Alves
Novel technologies and AI: state of the art
Søren Petersen
Novel technologies and AI: consensus recommendations
Luca Vitale
Novel technologies and AI: open questions for research
Henry Wood
Gene and cellular therapy: European registries and collaboration
Elena Matei
Gene and cellular therapy: what is new in the clinic
Andreas Fuchs
Gene and cellular therapy: open questions for research
Étienne Lefebvre
Lymphoma: perspectives from both sides of the Atlantic
Frank Becker
Lymphoma: regional differences in practice
Lukas Roth
Lymphoma: access to novel therapies
Matteo Greco
Myeloma and plasma cell disorders: regional differences in practice
Anders Bengtsson
Myeloma and plasma cell disorders: joint research priorities
Carolin Werner
Myeloma and plasma cell disorders: access to novel therapies
Tomasz Grabowski
Myeloproliferative neoplasms: joint research priorities
Jian Chen
Myeloproliferative neoplasms: perspectives from both sides of the Atlantic
Bruno Carvalho
Myeloproliferative neoplasms: regional differences in practice
David Hill
Acute myeloid leukemia: joint research priorities
Mehmet Koç
Acute myeloid leukemia: perspectives from both sides of the Atlantic
Mustafa Arslan
Acute myeloid leukemia: regional differences in practice
Jan Jung
Opening plenary lecture: Hematology at the frontier of cell and gene therapy
Wei Lin
Plenary lecture: Clonal hematopoiesis, aging and disease
John Edwards
Presidential symposium: Curing myeloma — a realistic goal?
Thijs Bakker
Presidential symposium: Precision medicine in acute leukemia
Ana Nikolić
Presidential symposium: Equity of access to advanced therapies in Europe
Bram Vos
Best of EHA2023: malignant hematology
Fatma Özdemir
Best of EHA2023: non-malignant hematology
Magnus Gustafsson
Best of EHA2023: translational research
Brian Edwards
EHA Lifetime Achievement Award Lecture
Can Arslan
Meet-the-Expert: Bleeding, thrombosis and platelets
Hugo Petit
Meet-the-Expert: Myelodysplastic syndromes
Richard King
Meet-the-Expert: Gene and cellular therapy
Takuya Kato
Meet-the-Expert: Lymphoma
Johannes Schmitt
Meet-the-Expert: Stem cell transplantation
Lucas Nascimento
Meet-the-Expert: Transfusion medicine
Fabio Martini
Meet-the-Expert: Acute lymphoblastic leukemia
Henry Wood
Meet-the-Expert: Myeloma and plasma cell disorders
Fatma Özdemir +2
Nordheim Pharma Satellite Symposium: Redefining depth of response in multiple myeloma
Anders Poulsen +2
Corvalis Biotherapeutics Satellite Symposium: Bispecific antibodies across lines of therapy in B-cell lymphoma
Jan Möller +2
Hemavera Therapeutics Satellite Symposium: Iron, inflammation and anemia: new targets
Matthew Baker +2
Lumora Oncology Satellite Symposium: Targeting menin in acute leukemia
Andrew Martin +2
Astelis Bio Satellite Symposium: Gene therapy for hemoglobinopathies in practice
Jelena Jurić +2
Medrion Life Sciences Satellite Symposium: Managing triple-class exposed myeloma
Alejandro Torres +2
Vireon Biotech Satellite Symposium: Allogeneic CAR T: ready for the clinic?
Tobias Keller +2
Kaluna Pharma Satellite Symposium: Fixed-duration therapy in CLL